Bajaj Healthcare, on Friday, requested regulatory clearance for Posaconazole API, used in treating Mucormycosis (black fungus) infection in Covid-19 patients.
Over 11,000 cases of the infection, a post-Covid side-effect, have been reported across India
Bajaj Healthcare, on Friday, requested regulatory clearance for Posaconazole API, used in treating Mucormycosis (black fungus) infection in Covid-19 patients.
Bajaj Healthcare claimed in a regulatory filing that it has acquired approval from the FDA (Food and Drug Administration) in Gandhi Nagar, Gujarat (India) to manufacture and market Posaconazole API as an authorised drug for treating Mucormycosis in India.
Bajaj Healthcare has stated that commercial production will begin in the first week of June 2021.
Posaconazole is a triazole antifungal medication used to treat Mucormycosis. Over 11,000 cases of black fungus infection have been detected across the country, prompting state governments to label the outbreak an epidemic.
We expect that the availability of an effective drug like Posaconazole would relieve the pressure and provide patients with a much-needed and timely therapy option, according to Anil Jain, Joint Managing Director, Bajaj Healthcare.
FDA Gandhi Nagar, Gujarat (India) has granted licence to manufacture and distribute the Posaconazole API in the domestic and international markets, according to the company.